Comparative study between intravenous and subcutaneous administration of cladribine in treatment of hairy cell leukemia patients
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Nehad M. Tawfik & Aml Soliman Nasr
- چاپ و سال / کشور: 2011
Description
Cladribine is a cytotoxic agent with high activity in hematological malignancies. It is usually administered intravenously. The study was carried out on 20 Egyptian hairy cell leukemia cases; 17 cases were de novo, and 3 cases were relapsed. Four (20%) were treated with IV cladribine, and 16 (80%) were treated with subcutaneous (SC) cladribine. An average duration of response was 36 months with no relapses in cases receiving IV cladribine vs. 25% relapse rate in cases receiving SC cladribine, with no significant difference between them. The subcutaneous administration of cladribine has a positive benefit/risk ratio in the treatment of patients with hairy cell leukemia.
Comp Clin Pathol DOI 10.1007/s00580-011-1277-5 Received: 27 March 2011 / Accepted: 22 June 2011
